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Introduction
Cancer, as the third cause of
mortality after cardio-vascular
diseases and accidents, is widespread
among Iranian women.1,2 Breast
cancer as a social problem is
increasing in all countries. After lung
cancer, it is the most common cause
of cancer-related deaths. The
prevalence rate of breast cancer in
global studies has been reported to be
12.5%. This statistical data suggests
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that one out of 8 women is at risk of having breast
cancer in her lifetime.3 Of all cancers related to
women in Iran, 25% are breast cancer cases, with
women affected one decade earlier than other
women worldwide.4 Breast cancer can be a fatal
disease that affects patients mentally and psy-
chologically. Therefore, breast cancer and its
treatment considerably affect patients' mental and
social health, as well as quality of life.5
Cognitive impairment occurs in 16%-75% of
cancer cases, affecting attention, concentration,
and memory.6,7 The changes in cognitive function
also impact quality of life in patients.8,9 Although
the cause of cognitive impairment in patients with
cancer is unclear, it seems that the use of anticancer
and neurodegenerative drugs cause varying
degrees of cognitive impairment.10 In addition,
anti-estrogen therapies that use tamoxifen trigger
changes in cognitive function.11 Therefore,
treatment of this disease affects the cognitive
ability of patients.12,13
Among the components of cognitive function,
attention is an essential factor for the efficiency
of cognitive function. Therefore, understanding the
problems related to attention is an important step
in treating patients with cancer.14
This study examined perceived cognitive
function in patients with breast cancer and
determined the main predictors of changes in
cognitive function following treatment. The study
findings might be employed to design intervention
programs to prevent or minimize these disorders.
Materials and Methods
This analytical cross-sectional study was
performed on 96 women receiving adjuvant
treatment after surgery and who had already
received adjuvant treatment. Each patient had a
pathologically confirmed diagnosis of cancer.
The statistical population comprised patients
with breast cancer. Exclusion criteria were
metastatic disease or relapse, approved prior
neurological or psychological disorders, the use
of drugs that affect cognitive function, and
addiction to drugs or alcohol. We selected the
study patients from the Cancer Registry in Ardabil,
Iran, private clinics and the Oncology Ward of
Imam Khomeini Hospital in Ardabil.
In this study, the Attentional Function Index
(AFI) was used to measure perceived cognitive
function.15,16 The AFI consists of 16, 100 mm
visual analogue scales (VASs) that range from 0
(not at all) to 100 (extremely well). Individuals
self-rate how well they are able to perform
cognitive activities such as planning daily
activities, getting started on tasks, keeping a train
of thought, remembering to do important things,
and attention to details. Participants were asked
to place a mark through the horizontal line at
whatever point best described how well they were
functioning at that time.
The validity and reliability of the technique
have been established in healthy and unhealthy
populations.15,16 Cronbach's alpha for the
questionnaire was estimated at 74% in this study.
We used the following formula to calculate
sample size for this study: 
n= (Z1-σ/2)2(σ)2/ d2
Previous literature used to estimate variance,
which was 5 for the calculated sample size in
this study. A maximum error of 1 was accepted in
this study with a probability of 95%. We chose α
value of 5% (0.05). Due to the lack of detailed data
recording on patients with breast cancer and the
obstacles to patient access, we performed non-
random sampling.
Initially, we extracted information related to
patients that included personal information and
addresses. Next, we met with the patients and
discussed the study objectives, method, and
questionnaire. Patients signed a consent form to
participate. SPSS version 16.0 was used to analyze
the data. Descriptive statistics were used to
describe demographic and clinical characteris-
tics of the sample. We used the t-test and one
way analysis of variance (ANOVA) to compare the
differences in AFI scores to demographic and
medical characteristics.
Results
Patients had a mean age of 44.7±1 years with
an age range of 20-66 years.There were 51
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(53.1%) who were in the age group of 41-50
years, which represented the majority of patients.
A total of 28(29.2%), had high school diplomas
and college/university degrees. There were 85
(88.5%) married patients and 8 (8.3%) were
employed. The number of patients who had
mastectomies was 67 (69.8%). According to the
type of nonsurgical treatment received at the time
of the study, 72.8% of patients had undergone
chemotherapy, 18.3% had hormone therapy, 4.2%
received radiotherapy, and 4.2% underwent
combined treatment.
The time lapse after diagnosis was 6-12 months
in 46.9% of patients (Table 1).
Patients’ mean AFI score was 59.53±1.69. We
compared mean scores for cognitive function in
terms of demographic variables and disease char-
acteristics.
Patients' mean AFI score was 61.32±14.1 for
those under 50 years of age and 51.22±24.9 for
patients age 50 and older. There was a statistically
significant difference between AFI scores at the
age of 50 years and above (P=0.02).
The comparison of mean scores revealed that
AFI scores were higher in patients with high
school diplomas or college/university degrees
compared to those with lower levels of education
(P<0.001).There was no significant difference
between AFI scores with respect to the type of
surgery (P=0.3).
There was a statistically significant difference
between AFI scores in terms of current non-
surgical treatment (P<0.001). People who
underwent radiotherapy had higher scores
compared to those who received hormone therapy
or chemotherapy.
Regarding the time lapse after disease
diagnosis, we observed a statistically significant
difference between AFI scores (P<0.001).
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Table 1. Comparison of perceived cognitive function according to demographic and medical characteristics.
Number (%) Mean score for cognitive function P-value
Age group (years)
<50 79(82.3) 61.32±14.1 0.02
≥50 17(17.7) 51.22±24.9
Education
Primary and lower 68(70.8) 54.15±15.1 <0.001
High school and university 28(29.2) 72.6±13.3
Marital status
Married 85(88.5) 62.4±15.1 <0.001
Single 7(7.3) 44.2±11.02
Widow 4(4.2) 25.3±3.05
Employment status
Employed 8(8.3) 71.7±19.8 0.03
Housewife 88(91.7) 58.4±16
Type of surgery
Breastconservation 29(30.2) 62.25±14.9 0.3
Mastectomy 67(69.8) 58.35±17.5
Current treatment
Chemotherapy 70(72.8) 56.3±15 <0.001
Hormone therapy 18(18.8) 43.9±20.7
Radiotherapy 4(4.2) 65.6±11
Combined 4(4.2) 65.38±14.8
Elapsed time after diagnosis
<6 months 14(14.6) 65.3±13.2 <0.001
6-12 months 45(46.9) 60.4±16.1
1-3 years 16(16.7) 54.8±16.5
3-5 years 11(11.5) 43.3±14.5
>5 years 10(10.4) 72.6±12.9
Nasrin Fouladi et al.
Discussion
The present study intended to determine
perceived cognitive function with regard to
attention in patients with breast cancer and identify
the factors that predict its change. In this study, the
mean AFI score was 61.32 for patients under 50
years of age and 51.22 for those 50 and older.
The results of the present study agreed with
findings by Seongmi et al., however they
contradict those reported by Chen et al.13,17
The results of this study were similar to a study
conducted by Cimprich et al., where the current
identified age was a predictor of cognitive
impairment in patients with breast cancer. Patients
who were older suffered from more severe
cognitive disorder.18
In the present study, patients who had higher
educational degrees obtained better scores. These
results supported those of Seongmi et al. and
Cimprich et al., which suggested that level of
education could predict cognitive impairment in
patients with breast cancer. Patients with lower
levels of education had more serious cognitive
disorders.17,18
Previous studies reported significant differences
between the scores of patients who had breast
conserving surgery and those who underwent
radical mastectomy.17 This finding contrasted the
results of the current study, which showed no
statistically significant difference between AFI
scores in terms of the type of surgery. However,
the scores of patients who underwent breast
conserving surgery were higher than those who
underwent mastectomy.
In terms of the type of treatment following
surgery, the results demonstrated that patients
who received chemotherapy and hormone therapy
had lower AFI scores compared to other patients.
Chemotherapy-related cognitive impairment
was the most widely reported source of cognitive
deficit in cancer patients, particularly in breast
cancer. Recently, physiological evidence showed
that chemotherapy seemed to affect cerebral white
matter integrity which might reflect mild cognitive
impairment.17,19
Paganini et al. found that anti-estrogen drugs
such as tamoxifen could cause cognitive
dysfunction.11 Likewise, Phillips et al. showed
that tamoxifen use could lead to cognitive
impairment in patients.19
In the current study, AFI scores varied among
patients regarding the amount of time elapsed
after the cancer diagnosis. In the patients where
five years or more had passed after diagnosis,
the AFI scores demonstrated a dramatic increase.
Biglia et al. reported a significant decrease in
patients’ attentional function after 6 months of
chemotherapy treatment.20
Considering the decreased attention during the
first years following treatment, therapeutic
interventions can be an appropriate action to be
taken for patients during this period.
Conclusion
The results of the present study indicated that
chemotherapy and hormone therapy, increased
age, low education level, and short time after
diagnosis could affect cognitive function in
patients with breast cancer. However, AFI is a self-
report tool where it is likely that real problems
experienced by patients in their daily lives are not
reflected. Hence, it is recommended to conduct
additional studies that employ objective tools in
the future.
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